# Wuxi Biortus Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-biortus-biosciences-co

- Industry: Pharmaceuticals
- Headquarters: Jiangyin, China
- Website: www.biortus.bio
- Total disclosed funding: $31M
- Latest round: Series B (Nov 5, 2021)
- Investors on record: 3

## About

Established in 2009 and headquartered in Jiangyin, China, Wuxi Biortus Biosciences Co., Ltd. was founded by Jiangsu Shuangliang Group and a team of scientists with international pharmaceutical R&D experience. The company provides contract research services centered on complex protein preparation, structural biology and cryo-electron microscopy (cryo-EM). Its technology platforms include protein expression and purification, bioanalysis and compound screening, crystal structure analysis and cryo-EM imaging. In October 2025, Pharmaron Beijing Co., Ltd. agreed to acquire 82.54% stake in the company for approximately CNY 1.35 billion.

The company provides comprehensive CRO services for early-stage drug discovery, including protein production, assay development, structural analysis and molecular modeling. The company operates core technology platforms in protein science, crystallography and cryo-electron microscopy. Its service portfolio includes protein and structure galleries such as SLC29A1, PknB, and BRD2, supporting the design and validation of new therapeutic targets.

The company generates revenue through contract-based research services with biopharmaceutical companies, offering customized structural biology and drug discovery projects.

Following its acquisition by Pharmaron Beijing Co., Ltd., the company will continue integrating structural biology and protein analysis capabilities into Pharmaron Beijing Co., Ltd.’s existing biologics platform to expand large-molecule discovery services.

## Funding rounds

- Series B, Nov 5, 2021, $31M — Legend Capital, Sherpa Healthcare Partners, Kangjun Capital
- Series A, Oct 9, 2020 — Kangjun Capital

## Investors

- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series A, Series B
- Legend Capital — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B